CDKN2A and urinary bladder cancer: In agreement with prior literature, significant copy number alterations involved deletion of CDKN2A/B, leading to cell cycle dysregulation, and focal amplifications in CCND1 and MDM2, which are well-documented events in bladder cancer [21].